Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer

Míreanna comhchosúla

• Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
  de réir: Jinyao Zhang, et al.
  Foilsithe / Cruthaithe: (2021-12-01)
• Virtual screening of Osimertinib and Dacomitinib Analogues with potential activity on EGFR (T790M and l858R Mutations) for non-small cell lung cancer treatment
  de réir: Leydis Luna Torres, et al.
  Foilsithe / Cruthaithe: (2021-10-01)
• The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study
  de réir: Wen-Chien Cheng, et al.
  Foilsithe / Cruthaithe: (2024-02-01)
• Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib
  de réir: Jian Liu, et al.
  Foilsithe / Cruthaithe: (2024-01-01)
• Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer
  de réir: Ji Eun Shin, et al.
  Foilsithe / Cruthaithe: (2025-02-01)